Evidence map›Paper›PMID 37455731›Full record

ArticleFrontiers in microbiology2023

Investigation of multidrug-resistant plasmids from carbapenemase-producing

Christine Lascols, Blake Cherney, Andrew B Conley, Lavanya Rishishwar, Matthew A Crawford, Stephen A Morse, Debra J Fisher, Kevin Anderson, David R Hodge, Segaran P Pillai and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Plasmid-Mediated Co-Occurrence ofTransboundary and emerging diseases · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Christine LascolsNational Center for Emerging and Zoonotic Infectious DiseasesCenters for Disease Control and Prevention, Atlanta, GA, United States.
Blake CherneyNational Center for Emerging and Zoonotic Infectious DiseasesCenters for Disease Control and Prevention, Atlanta, GA, United States.
Andrew B ConleyIHRC, Inc., Atlanta, GA, United States.
Lavanya RishishwarIHRC, Inc., Atlanta, GA, United States.
Matthew A CrawfordDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, United States.
Stephen A MorseIHRC, Inc., Atlanta, GA, United States.
Debra J FisherDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, United States.
Kevin AndersonScience and Technology Directorate, U.S. Department of Homeland Security, Washington, DC, United States.
David R HodgeScience and Technology Directorate, U.S. Department of Homeland Security, Washington, DC, United States.
Segaran P PillaiOffice of the Commissioner, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Molly A HughesDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, United States.
Erum KhanDepartment of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
David SueNational Center for Emerging and Zoonotic Infectious DiseasesCenters for Disease Control and Prevention, Atlanta, GA, United States.
National Center for Emerging and Zoonotic Infectious Diseases · USUniversity of Virginia · USUnited States Department of Homeland Security · USAga Khan University · PKUnited States Food and Drug Administration · US

Funding

A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteriaR01AI150941 · NIAID · UNIVERSITY OF VIRGINIA · PI HUGHES, MOLLY A · 2020 to 2024
$3.1M
NIAID NIH HHS R01 AI150941
6 · The paper itself

Abstract

Objectives: The study aim was to investigate multidrug-resistant (MDR) plasmids from a collection of 10 carbapenemase-producing Methods: Plasmids were isolated from 10 clinical isolates of Results: All carbapenemase-producing Conclusion: This study highlights the complexity and diversity of the plasmid-based genetic background of carbapenemase-producing clinical isolates from Pakistan. This study emphasizes the need for characterization of MDR plasmids to determine their complete molecular background and monitor AMR through plasmid transmission between multi-resistant bacterial pathogens.

Indexed as

AMR data analysisAMR determinantsKlebsiella pneumoniaeMDR plasmidsnanopore hybrid assemblies

Identifiers

PMID37455731
PMCPMC10340517
OpenAlexW4382726301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.